Ascorbic ACID decreases the antifungal effect of fluconazole in the treatment of candidiasis

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 10, 2009, Pages

  Wang, Yan ^a   Jia, Xin Ming ^a,b,c   Jia, Jian Hui ^e   Li, Ming Bang ^a   Cao, Ying Ying ^a   Gao, Ping Hui ^a   Liao, Wan Qing ^d   Cao, Yong Bing ^a   Jiang, Yuan Ying ^a,f  

^a School of Pharmacy   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Ascorbic acid; Candida; Chemotherapy; Fluconazole

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; FLUCONAZOLE; GLUTATHIONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; MOUSE; NONHUMAN; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 70449400128     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05187.x     Document Type: Article

References (34)

1. Ellis M, Richardson M, de Pauw B. Epidemiology. Hosp. Med. 2000; 61: 605-609
2. Garber G. An overview of fungal infections. Drugs 2001; 61 (Suppl. 1): 1.-12.
3. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur. J. Cancer Care 2001; 10: 56-62. (Pubitemid 33699410)
4. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 1998; 44: 343-499.
5. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2000; 19: 897-914.
6. Van den Bossche H, Willemsens G, Cools W, Lauwers WF, Le Jeune L. Biochemical effects of miconazole on fungi II. Inhibition of ergosterol biosynthesis in Candida albicans. Chem. Biol. Interact. 1978; 21: 59-78. (Pubitemid 8373681)
7. Van den Bossche H, Willemsens G, Cools W, Marichal P, Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem. Soc. Trans. 1983; 11: 665-667 (Pubitemid 14177066)
8. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azotes and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 2000; 44:2693-2700
9. Kobayashi D, Kondo K, Uehara N et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. 2002; 46: 3113-3117 (Pubitemid 35052614)
10. Li W, Maeda N, Beck. MA. Ascorbic acid deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. J. Nutr. 2006; 136: 2611-2616 (Pubitemid 44521622)
11. Arroll B. Non-antibiotic treatments for upper-respiratory tract infections (common cold). Respir. Med. 2005; 99: 1477-1484 (Pubitemid 41683928)
12. Cathcart III RF. Ascorbic acid in the treatment of acquired immune deficiency syndrome (AIDS). Med. Hypotheses 1984; 14:423-433 (Pubitemid 15195232)
13. Stephensen CB, Marquis GS, Jacob RA, Kruzich LA, Douglas SD, Wilson CM. Vitamins C and E in adolescents and young adults with HIV infection. Am. J. Clin. Nutr. 2006; 83: 870-879 (Pubitemid 44713153)
14. Kim HJ, Kim MK, Chang WK, Choi HS, Choi BY, Lee SS. Effect of nutrient intake and Helicobacter pylori infection on gastric cancer in Korea: A case-control study. Nutr. Cancer 2005; 52:138-146 (Pubitemid 41579756)
15. Baysoy G, Ertem D, Ademoǧlu E, Kotiloǧlu E, Keskin S, Pehlivanoǧlu E. Gastric histopathology, iron status and iron deficiency anemia in children with. Helicobacter pylori infection, J. Pediatr. Gastroenterol. Nutr. 2004; 38: 146-151
16. Park. JH, Kim SY, Kim DW, Lee WG, Rhee KH, Youn HS. Correlation between Helicobacter pylori infection and ascorbic acid levels in whole blood, plasma, and gastric juice, and the pH of gastric juice in Korean children. J. Pediatr. Gastroenterol. Nutr. 2003; 37: 53-62.
17. Comet M, Bidard F, Schwarz P et al. Deletions of endocytic components VPS28 and VPS32 affect growth at alkaline pH and virulence through both RIM. 101-dependent and RIM101-independent pathways in Candida albicans. Infect. Immun. 2005; 73: 7977-7987 (Pubitemid 41740283)
18. Zhang L, Yan K, Zhang Y et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl Acad. Sci.. USA 2007; 104:4606-4611 (Pubitemid 47186272)
19. Maki K, Holmes AR, Watabe E et al. Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations. Microbiol. Immunol. 2007; 51:1053-1059 (Pubitemid 350145854)
20. -/- knockout mice. Antimicrob. Agents Chemother. 2002; 46: 1240-1245
21. Pitzurra L, Fringuelli R, Perito S et al. A new azote derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cells. Antimicrob. Agents Chemother. 1999; 43: 2170-2175 (Pubitemid 29421196)
22. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P. Fluconazole plus cyclosporine: A fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. 2000; 44: 2932-2938 (Pubitemid 30803046)
23. Miyazaki T, Miyazaki Y, Izumikawa K et al. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother. 2006; 50: 580-586 (Pubitemid 43190969)
24. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 2006; 50:1293-1297
25. Hope WW, Drusano GL, Moore CB et al. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 2007; 51: 285-295
26. Venkatesh MP, Pham D, Fein M, Kong L, Weisman LE. Neonatal coinfection model of coagulase-negative Staphylococcus (Staphylococcus epidermidis) and Candida albicans: Fluconazole prophylaxis enhances survival and growth. Antimicrob. Agents Chemother. 2007; 51: 1240-1245 (Pubitemid 46586800)
27. Quan H, Cao YY, Xu Z et al. Potent in vitro synergism of fluconazole and befberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob. Agents Chemother. 2006; 50: 1096-1099 (Pubitemid 43327820)
28. National Committee for Clinical and Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Vol.17, No.9. Approved Standard M27-A. National Committee for Clinical and Laboratory Standards, Wayne, PA. 1997.
29. Kesavan C, Raghunathan M, Ganesan N. Morphological and growth altering effects of Cisplatin in C. albicans using fluorescence microscopy. Ann. Clin. Microbiol. Antimicrob. 2005; 4: 7. (Pubitemid 41461202)
30. Tucker RM, Williams PL, Arathoon EG et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 1988; 32: 369-373
31. Carrasco-Portugal Mdel C, Flores-Murrieta FJ. Gender differences in the oral pharmacokinetics of fluconazole. Clin. Drug Invest. 2007; 27: 851-855
32. Silling G. Fluconazole: Optimized antifungal therapy based on pharmacokinetics. Mycoses 2002; 45 (Suppl 3): 39-41.
33. Salganik RI. The benefits and hazards of antioxidants: Controlling apoptosis and other protective mechanisms in cancer patients and the human population J. Am. Coll. Nutr. 2001; 20 (Suppl): S464-72.
34. Huh WK, Kim ST, Kim H, Jeong G, Kang SO. Deficiency of Derythroascorbic acid attenuates hyphal growth and virulence of Candida albicans. Infect. Immun. 2001; 69: 3939-3946 (Pubitemid 32493316)